In October, Cure JM had two speakers give an update about drug discovery in juvenile myositis. Joni L. Rutter, Ph.D., Director, National Center for Advancing Translational Sciences, National Institutes of Health, updated families about the process of drug discovery and development and how partnerships like Cure JM’s NCATS partnership accelerate new treatments for juvenile myositis. Eric Hoffman, Ph.D., President and CEO, of ReveraGen Pharmaceutical, brought families into the inner circle of understanding how new drugs move through the process and the role that Cure JM, parents, patients, and grandparents play in this process.
Click the link above to watch the informative presentation.
